Literature DB >> 6987030

Comparison of methods of evaluating nephrotoxicity of cis-platinum.

B R Jones, R B Bhalla, J Mladek, R N Kaleya, R J Gralla, N W Alcock, M K Schwartz, C W Young, M M Reidenberg.   

Abstract

The urinary excretion of leucine aminopeptidase (LAP), N-acetyl-beta-glucosaminidase (NAG), and beta 2-microglobulin was measured in 12 cancer patients receiving cis-platinum to evaluate the sensitivity of these indices for renal tubular damage. NAG and LAP excretion rose markedly in all patients, and beta 2-microglobulin rose in 11. Seven of the 9 patients who had received cis-platinum 6 wk before the study had prestudy dose elevations of one or more of these indices. We conclude that these urinary proteins are sensitive indicators of proximal renal tubular injury and may provide greater sensitivity for comparison of the nephrotoxic potential of future platinum analogs or for assessing the efficacy of regimens designed to protect the kidney from platinum nephrotoxicity than other measurements. The persistence of high excretion vales for these indices 6 wk after a dose demonstrates the persistent renal injury by cis-platinum.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6987030     DOI: 10.1038/clpt.1980.79

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  29 in total

Review 1.  Cisplatin nephrotoxicity. A review.

Authors:  G Daugaard; U Abildgaard
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Simplified microchip electrophoresis for rapid separation of urine proteins.

Authors:  Hongwei Song; Huimin Wang; Saoqing Ju; Qinghui Jin; Chunping Jia; Hui Cong
Journal:  J Clin Lab Anal       Date:  2014-01-06       Impact factor: 2.352

3.  Phase I study of the cisplatin analogue 1,1-diamminomethylcyclohexane sulfatoplatinum (TNO-6) (NSC 311056).

Authors:  J B Sørensen; S Groth; S W Hansen; M H Nissen; M Rørth; H H Hansen
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

4.  Inhibitory effects of calmodulin antagonists on urinary enzyme excretion in rats after nephrotoxic doses of mercuric chloride.

Authors:  S D Harrison; J L Cox; R C Giles
Journal:  Bull Environ Contam Toxicol       Date:  1985-03       Impact factor: 2.151

5.  Evaluation of the nephrotoxicity of iproplatin (CHIP) in comparison to cisplatin by the measurement of urinary enzymes.

Authors:  L Pendyala; S Madajewicz; S B Lele; S G Arbuck; P J Creaven
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

6.  Assessment of renal function during high-dose cis-platinum therapy in patients with ovarian carcinoma.

Authors:  P K Buamah; A Howell; H Whitby; E S Harpur; A Gescher
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

7.  Renal function was not impaired by treatment with 5-aminosalicylic acid in rats and man.

Authors:  U Diener; H V Tuczek; C Fischer; K Maier; U Klotz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-06       Impact factor: 3.000

Review 8.  Cisplatin: a review of clinical applications and renal toxicity.

Authors:  D T Sleijfer; S Meijer; N H Mulder
Journal:  Pharm Weekbl Sci       Date:  1985-12-13

9.  Follow-up study of enzymuria and beta 2 microglobulinuria during cis-platinum treatment.

Authors:  A S Tirelli; N Colombo; G Cavanna; C Mangioni; B M Assael
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

10.  Urinary beta 2-microglobulin: early indicator of high dose cisdiamminedichloroplatinum nephrotoxicity? Influence of furosemide.

Authors:  C de Gislain; M Dumas; P d'Athis; J L Lautissier; A Escousse; J Guerrin
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.